ALLMedicine™ Anal Cancer Center

Feb 3rd, 2023 - Localized anal cancer is mostly represented by squamous cell carcinoma of the anus (SCCA) and is cured in ≥80 % of cases by chemoradiation (CRT). Development of techniques for detection/evaluating circulating tumor cells (CTCs) for diagnosis/ prog...

Feb 3rd, 2023 - In the United States, the effectiveness of anal cancer screening programs has been limited by a lack of trained professionals proficient in high-resolution anoscopy (HRA) and a high patient lost-to-follow-up rate between diagnosis and treatment. S...

Jan 31st, 2023 - PRIMARY OBJECTIVE: I. To evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves disease-free survival (DFS) compared with observation in patients with high risk anal carcinoma. SECONDARY OBJECTIVES: I. To compar...

Jan 31st, 2023 - PRIMARY OBJECTIVE: I. To demonstrate that anti-PD-1 therapy in combination with carboplatin/weekly paclitaxel results in improved progression-free survival (PFS) versus systemic chemotherapy alone. SECONDARY OBJECTIVES: I. To demonstrate that anti...

Jan 30th, 2023 - PRIMARY OBJECTIVES: I. To determine the safety of reduced intensity chemo-radiation therapy (CRT) in low-risk disease. II. To determine the safety of nivolumab after standard CRT in high-risk disease. SECONDARY OBJECTIVES: I. To estimate the effic...

Jun 19th, 2022 - Previous anal cancer guidelines delineate target volumes similarly for all patients with squamous cell carcinoma of the anal canal and/or perianal skin (SCCA), regardless of disease stage. The purpose of this guideline is to provide customized rad...

Jun 28th, 2021 - Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.|2021|Rao S,Guren MG,Khan K,Brown G,Renehan AG,|diagnosis,epidemiology,therapy,

Aug 14th, 2018 - People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment ...

Jul 15th, 2018 - The NCCN Guidelines for Anal Carcinoma provide recommendations for the management of patients with squamous cell carcinoma of the anal canal or perianal region. Primary treatment of anal cancer usually includes chemoradiation, although certain les...

Aug 26th, 2016 - To define minimum standards for provision of services and clinical practice in the investigation of anal cancer precursors. After initial face to face meetings of experts at the International Papillomavirus meeting in Lisbon, September 17 to 21, 2...

Jan 31st, 2023 - PRIMARY OBJECTIVE: I. To evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves disease-free survival (DFS) compared with observation in patients with high risk anal carcinoma. SECONDARY OBJECTIVES: I. To compar...

Jan 31st, 2023 - PRIMARY OBJECTIVE: I. To demonstrate that anti-PD-1 therapy in combination with carboplatin/weekly paclitaxel results in improved progression-free survival (PFS) versus systemic chemotherapy alone. SECONDARY OBJECTIVES: I. To demonstrate that anti...

Jan 30th, 2023 - PRIMARY OBJECTIVES: I. To determine the safety of reduced intensity chemo-radiation therapy (CRT) in low-risk disease. II. To determine the safety of nivolumab after standard CRT in high-risk disease. SECONDARY OBJECTIVES: I. To estimate the effic...

Jan 25th, 2023 - In this Phase 1/2 study, the investigators will conduct a safety and efficacy study of the combination of BMX-001 with standard radiation therapy (RT) and concurrent 5-fluorouracil (5FU)/mitomycin in newly diagnosed Anal Squamous Cell Carcinoma (A...

Jan 19th, 2023 - Inclusion criteria: Patients > 18 years of age operated with robotic-assisted abdominoperineal resection for irradiated locally advanced rectal or anal cancer where robotic-assisted perineal and/or vaginal reconstruction has been performed with a ...

Jan 13th, 2023 - Screening HIV-positive individuals for early signs of anal cancer may lead to an earlier diagnosis and better survival, according to an observational Dutch cohort study. Among men who have sex with men (MSM) living with HIV, anal cancer-related mo...

Jan 12th, 2023 - Neoadjuvant immunotherapy with PD-1 inhibitors led to objective responses in 85% of patients with localized and locally advanced colorectal cancer (CRC) with mismatch repair deficiency (dMMR)/high microsatellite instability (MSI-H), a retrospectiv...

Oct 5th, 2022 - The FDA has granted a fast track designation to CUE-101 for use as a monotherapy and in combination with pembrolizumab (Keytruda) in patients with human papillomavirus (HPV16+) recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)....

Sep 22nd, 2022 - Could a novel noninvasive gastric mapping device that measures stomach activity offer new insights into chronic nausea and vomiting? (Science Translational Medicine) Vedolizumab (Entyvio) and ustekinumab (Stelara) were both highly effective as thi...

Sep 21st, 2022 - Zanidatamab zovodotin (ZW49) was found to produce encouraging responses and to have a manageable toxicity profile when used as a monotherapy in heavily pretreated patients with HER2-positive solid cancers, according to data from a first-in-human p...